πŸ‡ΊπŸ‡Έ FDA
Patent

US 12043831

Modulation of alpha synuclein expression

granted A61PA61P21/00A61P25/00

Quick answer

US patent 12043831 (Modulation of alpha synuclein expression) held by Ionis Pharmaceuticals, Inc. expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P21/00, A61P25/00, A61P25/02, A61P25/16